trial

Impact of tDCS on Cannabis Craving in Schizophrenia

NCTId NCT05784961
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Not Yet Recruiting
Enrollment 138 (estimated)
Sponsored by Centre hospitalier de Ville-Evrard, France
Primary completion 2027-03-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Not Yet Recruiting
Enrollment
138 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2024-03-01
Primary completion
2027-03-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
TDCS

Sponsors

Centre hospitalier de Ville-Evrard, FranceLead Sponsor

Sites

2 total
Neuilly-sur-Marne, FranceNeuilly-sur-Marne, France

Facts & assertions

4 sourced
Enrollment
138
Phase
NA
Primary Completion Date
2027-03-01
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
TDCS
drug
lead_sponsor
Centre hospitalier de Ville-Evrard, France
company
indication
Schizophrenia
indication
Cannabis Use Disorder
indication
Schizophrenia
indication